Literature DB >> 18782355

High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism.

Philippe Caron1, Jean Christophe Maiza, Claire Renaud, Catherine Cormier, Béatrice Herbault Barres, Jean Claude Souberbielle.   

Abstract

BACKGROUND: Primary hyperparathyroidism (PHP) is caused by parathyroid adenomas or hyperplasia, and occasionally by parathyroid carcinoma. Recently a high third generation/second generation PTH ratio has been observed in some patients with parathyroid carcinoma. PATIENTS AND METHODS: We report the case of a 60-year old woman who was presented a fourth episode of PTH-related hypercalcaemia due to a parathyroid carcinoma. Serum PTH levels were measured using a second generation assay and a third generation assay before, 4 and 7 months after the fourth surgery. Then, PTH levels were measured in 294 osteoporotic normocalcaemic patients as well as in 30 consecutive PHP patients.
RESULTS: Before surgery of the patient with parathyroid carcinoma, second generation PTH was 229 pg/ml, third generation PTH was 675 pg/ml and third generation/second generation PTH ratio was 2.95. Four and 7 months after surgery the third generation/second generation PTH ratio was 0.70 and 0.66, respectively. All osteoporotic patients had a normal third generation/second generation PTH ratio (0.585 +/- 0.118) whereas only one patient (3.3%) with PHP had a third generation/second generation PTH ratio > 1 (1.54).
CONCLUSION: A high third generation/second generation PTH ratio could be observed in patients with parathyroid carcinoma, is uncommon in benign PHP and is absent in osteoporotic patients without PHP. Therefore, PTH level can be measured using second and third generation assays in some PHP patients, and a specific surgical protocol for possible parathyroid carcinoma could be discussed in patients with a high third generation/second generation PTH ratio.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18782355     DOI: 10.1111/j.1365-2265.2008.03408.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Radiofrequency ablation of parathyroid adenoma in primary hyperparathyroidism.

Authors:  Byung Seup Kim; Tae Ik Eom; Kyung Ho Kang; Sung Jun Park
Journal:  J Med Ultrason (2001)       Date:  2013-09-20       Impact factor: 1.314

Review 2.  Diagnosis and management of parathyroid cancer.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Endocrinol       Date:  2012-07-03       Impact factor: 43.330

3.  Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.

Authors:  Philippe Caron; William F Simonds; Jean-Christophe Maiza; Mishaela Rubin; Tom Cantor; Louise Rousseau; John P Bilezikian; Jean-Claude Souberbielle; Pierre D'Amour
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

Review 4.  Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature.

Authors:  Aditya Dutta; Rimesh Pal; Nimisha Jain; Pinaki Dutta; Ashutosh Rai; Anil Bhansali; Arunanshu Behera; Uma Nahar Saikia; Vikarn Vishwajeet; David Collier; Hannah Boon; Márta Korbonits; Sanjay Kumar Bhadada
Journal:  J Endocr Soc       Date:  2019-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.